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An update on the use of biologic therapies
in the management of uveitis in Behçet’s
disease: a comprehensive review
Thomas W. McNally1, Erika M. Damato2,3, Philip I. Murray2,3,4,5, Alastair K. Denniston4,5,6* and Robert J. Barry4,5
Abstract
Behçet’s disease (BD) is a systemic vasculitis characterised by a relapsing remitting course, affecting multiple organ
systems. In the eye, it is a cause of potentially blinding inflammation in the form of uveitis. Management of uveitis
in BD often requires the use of systemic immunosuppression, in order to reduce disease activity and prevent
accumulation of irreversible damage. Whilst corticosteroids remain the mainstay of treatment, long-term use is limited
by the development of adrenocorticotrophic side effects. There has therefore been significant interest in the use of
corticosteroid-sparing immunosuppressive agents, and more recently, biologic therapies. Recent publications have
demonstrated biologic therapy to have beneficial effects both on overall disease control, and quality of life for patients
with BD. Widespread use of such agents is however limited, partly by the lack of high quality research evidence, and
partly by the prohibitive cost of biologic treatments. In this review, we discuss the most recent research investigating
the use of biologic therapy in uveitis due to BD, with consideration of health economics and quality of life outcomes.
Keywords: Behçet’s disease, Biologic therapy, Health economics, Immunosuppression, Quality of life, Steroid-sparing
agents, Uveitis
Background
Behçet’s disease (BD) is a multi-system inflammatory
disorder of unknown aetiology [1, 2]. Presentation is
variable, depending on the organ system involved and
the severity of the disease in each anatomical location
[3]. BD is characterised by relapsing and remitting epi-
sodes of inflammation and may present with ocular
manifestations, genital and oral apthae, gastrointestinal
involvement, skin lesions, neurologic disease, arthropa-
thy, and pulmonary, renal and vascular disease [4, 5].
No diagnostic test exists for BD, and accurate diagnosis
is therefore dependent on identification of clinical fea-
tures in accordance with internationally accepted diag-
nostic criteria [6]. The manifestations of the disease are
largely attributable to widespread vasculitis [7].
BD occurs throughout all geographic locations, being
most prevalent and often more severe in countries dis-
tributed along the ancient ‘Silk Route’ [8]. For example,
in the UK BD is considered an orphan disease, with an
estimated prevalence of 0.64 per 100,000, whilst preva-
lence increases to between 20 and 421 per 100,000 in
Mediterranean and Chinese populations [9]. BD typically
presents between 20 to 40 years of age; onset under the
age of 25 years tends to be associated with an increased
risk of ocular disease [7]. The condition is reported to
be most aggressive in Far-Eastern young males [10–13].
Although BD has traditionally been considered sporadic
there have been cases of familial clustering, suggesting a
potential genetic predisposition to disease [14, 15]. Gen-
etic anticipation, where the disease presents earlier in
subsequent generations, is also evident [16].
Evidence suggests that the pathogenesis of BD involves
an abnormal immune response following exposure to an
exogenous agent, possibly infective, in patients who are
genetically predisposed to the disease [17]. Several disease
mechanisms have been proposed, with significant evi-
dence supporting the involvement of human leukocyte
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antigen B51 (HLA-B51) [18–26]. More recently, there has
been interest in the possibility of associations between BD
and gut microbiota profiles. A particularly interesting as-
sociation has been observed with reduced butyrate pro-
duction, which is thought to be important in T-regulatory
cell development [27].
Non-infective uveitis is rare in the general population,
affecting 25–50 people per 100,000 in the UK. However,
it is the most common ocular manifestation of BD and
can involve the anterior, intermediate and posterior
uveal tract or either in isolation, or in combination as
panuveitis. Whilst there are no pathognomonic fea-
tures, uveitis in BD typically presents with acute onset
hypopyon and occlusive retinal vasculitis, with predom-
inant inflammation of retinal veins rather than arteri-
oles. Whilst uveitis due to BD is typically bilateral,
flares of inflammation usually occur unilaterally and
alternate between eyes [28]. Uveitis is associated with a
worse visual outcome in males with BD [29, 30] and
affects between 50% and 90% of BD sufferers depending
on the geographic location of the population [31]. Up
to 30% of patients with uveitis due to any cause experience
significant visual impairment or legal blindness [32]. In
addition to a reduced visual acuity patients can also suffer
from decreased contrast sensitivity, increased light sensi-
tivity, loss of depth and colour perception, floaters, glare
and secondary glaucoma with loss of visual field. Uveitis,
therefore, has a significant impact on quality of life [33].
In a cross-sectional study of 880 patients with BD,
30.9% and 24.2% of eyes in males and females respect-
ively had a potential visual acuity of 0.1 LogMAR or less.
It was predicted that the risk of loss of useful vision in
5 years was 21% in males and 10% in females, increasing
to 30% and 17% respectively after 10 years [34].
Given the variability in presentation and severity, there
are no widely-accepted ‘gold-standards’ in the treatment
of BD. Furthermore, access to treatment varies by
geographic location, often limiting the range of treat-
ment options available. Disease management is therefore
variable, with therapeutic options ranging from symp-
tomatic relief through to systemic immunosuppression.
Treatment is usually instigated and monitored by a
multi-disciplinary team, requiring collaboration between
dermatologists, ophthalmologists and rheumatologists,
with input from cardiologists, genitourinary physicians
and neurologists depending on presenting features.
In the following review, we consider the evidence
available to guide management of uveitis in BD, with
particular attention to biological agents. Until very re-
cently, there has been a paucity of high quality evidence
to support the use of biologic therapies in BD. How-
ever, outcomes of larger multicenter trials have recently
been reported, providing an increasing quantity of
convincing evidence for the benefit of biologic over
traditional therapies. We wished to review existing and
emerging literature in this field, and offer a clinical up-
date in the biologics for the control of Behçet’s uveitis.
Overview of current treatment strategies
Before considering recent advances in biologic therapy, it
is necessary to review existing management strategies, to
highlight both the strengths and weaknesses of current
practice. Since BD is of unknown aetiology, treatment
cannot be targeted at a specific causative agent. Thus,
disease must be controlled via suppression of the immune
response. Treatment of uveitis in BD typically relies on
the use of corticosteroids for acute exacerbations, with
other immunosuppressive agents introduced to achieve
long-term control.
Initial treatment of uveitis in BD depends on both the
severity and location of inflammation, highlighting the im-
portance of precise diagnosis [33]. The aim of treatment is
to control the inflammatory process in order to preserve
sight. For anterior uveitis, topical corticosteroids com-
bined with a cycloplegic agent are frequently used as a
first line therapy. For posterior segment disease, or recalci-
trant anterior uveitis, systemic therapy or local steroids
are often required. Whilst systemic corticosteroids are
commonly prescribed, long-term use is limited by the
development of unwanted side effects and a resulting
detrimental impact on quality of life. Potential side effects
include weight gain, hypertension, osteoporosis, mood
disturbance and glucose intolerance [33]. Despite these
limitations, corticosteroid therapy remains the mainstay of
acute management, owing to the rapid onset of immune
suppression [35]. Unfortunately, disease activity often re-
curs on cessation of therapy; adjunctive immunosuppres-
sive therapy is therefore used alongside corticosteroids to
enable reduction of corticosteroid dosage, minimize adre-
nocorticotrophic side effects, and hopefully reduce relapse
rates [36]. Such therapies are often referred to as “steroid
sparing agents” (SSA).
Numerous SSA have been used to treat BD, each with
varying cellular and biochemical targets. Whilst these
agents are free of the aforementioned adrenocorticotro-
phic effects, they each have potentially serious side effects
and require close monitoring [37, 38]. Table 1 summarises
conventional systemic immunosuppressive agents used to
treat non-infectious uveitis.
Biological therapies
Biological therapies, also known as biologic response
modifiers, have many potential advantages for the treat-
ment of uveitis in BD, particularly when traditional SSA
therapy fails or there is intolerance to medication. Biologic
agents are manufactured using recombinant DNA tech-
nology, designed with a detailed molecular understanding
of the pathogenesis of the immune response. They enable
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more targeted immune modulation and therefore tend to
have a more favorable side-effect profile, while offering a
greater efficacy. Biologic therapy may take the form of
monoclonal antibodies, cytokines, cytokine antagonists or
soluble receptors [33].
Much of the research to date employing biologic
agents for the treatment of uveitis has studied tumour
necrosis factor alpha (TNF- α) inhibitors, which have
been shown to significantly improve the outcome of uve-
itis in BD. Other biologic therapies are being developed
to target different aspects of the disease pathogenesis in-
cluding interleukin-1 (IL-1) and interleukin-6 (IL-6)
[39–41]. In addition, the use of interferons - particularly
interferon-α (IFN-α) - has shown promising outcomes in
the management of uveitis in BD [42]. Current biologic
therapies available for use in Behçet’s uveitis are summa-
rized in Table 2, and the available evidence discussed
throughout the following sections [43–48].
Search strategy
A systematic online literature search was performed
using the PubMed database, Medline, EMBASE and the
Cochrane Central Register of Controlled Trials
(CENTRAL) for all studies published before December
2016 combining the terms “therapy OR therapeutic OR
treatment”, “behçet*” (exploded), and all publication types
relating to clinical trials as listed in the PubMed database.
Abstracts were manually reviewed by two authors (RB and
TM) and all papers reporting outcomes of biologic therap-
ies were identified. To be considered for inclusion, all
documented cases of BD must have been diagnosed ac-
cording to the International Study Group (ISG) guidelines
(1990) [7], or for those studies recruiting patients prior to
the publication of these guidelines, diagnosis of BD must
have been deemed concordant with ISG criteria both
reviewing authors.
Publications were excluded from further review if
the study did not report outcomes of biologic ther-
apies, or did not specifically report outcomes for pa-
tients with BD. Duplicates, narrative reviews and
editorials were excluded from further analysis. Due
to the native language of the reviewers, we were un-
able to assess studies without an English language
translation.
Table 1 A summary of conventional systemic immunosuppressive agents used to treat non-infectious uveitis
Medication Mechanism Typical dosage Adverse effects Price of typical one-year
course of treatment for
Behçet’s uveitis (£GBP)a
T-cell inhibitors
Cyclosporine T-cell function inhibitor 2.5–10 mg/kg/day PO in 2
divided doses
Infections, nephrotoxicity, hypertension,
hirsutism and gingival hyperplasia
1111.43–4130.59
Tacrolimus T-cell function inhibitor 0.15–0.30 mg/kg/day PO Infections, nephrotoxicity, hypertension,





7.5–25 mg/week PO, SC,
or IM
Infections, hepatotoxicity, oral ulcers, fatigue,
alopecia, bone marrow suppression,
pneumonitis, fetal loss and gastrointestinal
disturbance
2271.36–4680.00
Azathioprine Purine metabolism inhibitor 1–4 mg/kg/day PO Infections, hepatotoxicity, fatigue, bone







500–1500 mg PO twice
daily





100 mg PO daily [×3 days],
then 20 mg PO daily or
every other day
Infections, bone marrow suppression,
diarrhoea, hypertension and fetal loss
373.27–746.54
Alkylating agents
Chlorambucil Alkylates nucleic acid 0.1–0.2 mg/kg/day PO Infections, bone marrow suppression,
increased risk of malignancy, and sterility
2365.78–4731.57
Cyclophosphamide Alkylates nucleic acid 1–3 mg/kg/day PO Infections, bone marrow suppression,
hemorrhagic cystitis, increased risk of





0.5–2 mg/day PO Infections, peripheral neuropathy, bone
marrow suppression, sterility and alopecia
265.54–1062.15
a Prices calculated according to recommended maintenance dose for one year of therapy for a 70 kg patient as prescribed and tested in up to date
literature. Price as per BNF 70 [Joint formulary committee. British National Formulary. BNF 70 ed. London: BMJ Group and Pharmaceutical Press;
September 2015]
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Tumour necrosis factor – Alpha (TNF-α) inhibitors
Rationale for TNF blockade in Behçet’s disease
Inflammation in BD is considered to be mediated pre-
dominantly by T helper type 1 (Th1) lymphocytes, releas-
ing cytokines such as Tumour Necrosis Factor (TNF) [49].
This is supported by the observation of increased numbers
of monocytes and T lymphocytes expressing the gamma-
delta receptor and increased levels of circulating TNF and
soluble TNF receptors in the peripheral blood of patients
with active disease [50–53]. Furthermore, high levels of
TNF have been detected in the aqueous humor of patients
with Behçet’s uveitis [54, 55].
There has therefore been significant interest in TNF
blockade, with several agents developed to inhibit TNF
signaling. Numerous targets have been identified in the
signaling pathway for potential therapeutic modulation.
These agents are discussed in further detail below.
Infliximab
There is considerable evidence accumulating to support
the efficacy of infliximab (Remicade; Janssen Biotech, Inc.,
Horsham, PA, USA) for the treatment of BD. Infliximab is
a chimeric monoclonal antibody directed against TNF and
has been shown to be effective and fast acting in the treat-
ment of Behçet-associated panuveitis [56–62].
Suhler et al. demonstrated the efficacy of infliximab in a
non-comparative case series of 23 patients with refractory
uveitis; four patients had BD, all of which had a diagnosis
of BD-related panuveitis [58]. Patients received 3 inflixi-
mab infusions at 0, 2 and 6 weeks at a dose of 3 mg/kg if
given alongside other immunosuppressive medications
(n = 20), or at 5 mg/kg if infliximab was given as mono-
therapy (n = 3). Patients who had responded to treatment
at week 10 were given a further infusion at week 14
(8 weeks after the loading schedule) and then every
8 weeks up to completion of the study at 50 weeks. Treat-
ment success was assessed by four outcome measures,
comprising end point visual acuity, control of intraocular
inflammation, improvement in inflammatory signs on
fluorescein angiography or optical coherence tomography,
and ability to reduce other anti-inflammatory medications.
Treatment was deemed successful if there was improve-
ment in any one of these four subcomponents, in the
absence of deterioration in any variable. According to
these criteria, success was reported in 18 out of 23 pa-
tients at the 10-week follow up point.
Table 2 A summary of selected biologics used to treat uveitis in Behçet’s Disease, their targets, doses, routes of administration and
side effects
Agent Target Route of
administration
Typical dosage Adverse effects Price of typical course
of treatment for
Behçet’s uveitis (£GBP)a
Tumour Necrosis Factor (TNF) inhibitors [41]
Infliximab TNF-α Intravenous Loading course of 3 × 3-5 mg/kg
doses at 2-week intervals, followed
by maintenance doses of 5-10
mg/kg at 4-week intervals [38]
Heart failure (congestive), infections,
(particularly reactivation of tuberculosis),
malignancy, thromboembolism, lupus-like
disease, hypersensitivity reactions, neoplasia
80,776.85
Adalimumab TNF-α Subcutaneous 40 mg injection at 2-week
intervals [38]
15,476.53
Etanercept TNF-α, β Subcutaneous 25 mg subcutaneously twice
weekly [42]
9295.00
Golimumab TNF-α Subcutaneous 50 mg every month [38] 9115.64
Specific receptor antagonists
Canakinumab IL-1β Intravenous or
subcutaneous
150 mg at 4–8 week intervals
[39]
Infections, nausea, abdominal discomfort 119,133.60
Tocilizumab IL-6 receptor Intravenous 4-12 mg/kg at 2–4 week intervals
[38, 43–45]
Infections and hypersensitivity reactions 1638.40
Anakinra IL-1 receptor Subcutaneous 1 mg/kg/day [38] Infections, injection-site reaction, headache,
fever and gastrointestinal disturbance
4466.14
Gevokizumab IL-1β Intravenous or
subcutaneous
0.3 mg/kg single infusion [38] Infections and hypersensitivity reactions n/ab
Lymphocyte Inhibitors
Rituximab B-cells via CD20 Intravenous 2 doses of 1 g 15 days apart [46] Infections, muscular spasms, gastrointestinal




Interferon α Non-specific Subcutaneous 6–9 MIU/day for 7 days, tapered
down to 3 MIU 3 times a week
and then discontinued [47]
Flu-like symptoms, bone marrow suppression,
injection-site reaction
4132.20
aPrices calculated according to recommended standard treatment dose and duration of course for a 70 kg patient as prescribed and tested in up to date
literature. Price as per BNF 70 [Joint formulary committee. British National Formulary. BNF 70 ed. London: BMJ Group and Pharmaceutical Press; September 2015]
bNo pricing is available
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All four patients with BD-related panuveitis showed
improvement in at least two of the reported outcome
measures, with two patients showing an improvement
in three outcomes. However, only one patient with BD-
related panuveitis demonstrated an improvement in vis-
ual acuity. This patient exhibited an improvement from
20/50 at week 0 to 20/30 at week 10 in both eyes. In
addition, two patients with BD experienced significant
adverse effects, although these were not severe enough
to warrant discontinuation of treatment: one patient
suffered recurrent vitreous haemorrhage that resolved
on observation, another had one episode of nephro-
lithiasis that was treated in the emergency department
and did not require admission. All patients with BD
completed the study. In contrast, five patients with uve-
itis due to other causes were unable to complete the
course of therapy due to adverse side effects, including
recurrent infections, hypersensitivity reactions and
heart failure.
Markomichelakis et al. reported the outcome of a
comparative study assessing the efficacy of a single
intravenous infusion of infliximab versus intravitreal
triamcinolone, demonstrating that infliximab was not
only better at reducing total ocular and fundus inflam-
mation, but was also faster acting than corticosteroid
therapy [60]. The prevalence of retinal vasculitis had re-
duced from 79% at baseline to 15% by 14 days follow-
up in the infliximab group, compared to 100% and
87.5% respectively in the intravitreal triamcinolone
acetonide group. Hamza et al. further demonstrated the
safety and efficacy of a single injection of 1 mg/0.05 ml
intravitreal infliximab in a series of 20 patients with re-
fractory uveitis due to BD. By 18 weeks follow-up, they
reported a statistically significant improvement in mean
visual acuity, reduction in mean central macular thick-
ness, and reduction in mean vitreous haze scores [62].
In 2008 the European League Against Rheumatism
(EULAR) Committee published recommendations for
the management of BD, in which they advocate the rou-
tine use of infliximab for patients with severe eye dis-
ease. Specifically, these recommendations state that any
patient with BD-associated eye disease should initially
be managed on a treatment regime that includes both
azathioprine and systemic steroids, with the addition of
either infliximab or cyclosporine A for patients with se-
vere eye disease. Alternatively, interferon-α therapy can
be used with or without corticosteroids [63].
Caution must however be exercised when using inflixi-
mab therapy due to potentially severe adverse side-effects
(Table 2). A 2016 study found 28% of patients experienced
side effects with 13% deemed ‘serious’, such as hypersensi-
tivity reactions (n = 10), autoimmune disease (n = 6) and
neoplasia (n = 4) [64]. These adverse effects are most
likely due to the murine origin of the variable region of
the molecule, and can be attenuated by concomitant anti-
histamine and pain-relief medication. More significantly,
there is an increased risk of developing disseminated TB,
and there have also been reported cases of demyelinating
disease in patients using TNF inhibitors; these risks are
common to all anti-TNF agents [65]. Patients should
therefore be screened for undiagnosed TB prior to com-
mencing biologic therapy, and these agents should be used
with caution in those at increased risk of demyelinating
disease. Patients prone to recurrent opportunistic infec-
tions should be monitored closely and those with active
infections should avoid therapy with this agent [39].
Adalimumab
Adalimumab (Humira; AbbVie, Inc., North Chicago, IL,
USA) is a human-derived monoclonal antibody directed
against TNF-α. It has predominantly been used when
infliximab has proven unsuccessful, or when patients opt
for subcutaneous infusions rather than intravenous in-
jections; in both cases it has been demonstrated to be
highly effective [66, 67]. A 40 mg injection once every
two weeks has been shown to be well tolerated, however
potential side effects including hypersensitivity reactions,
infections or heart failure have been reported [39], in
addition to the risks of TB and demyelination as discussed
above. It has also been demonstrated as a successful first
line treatment:
A 2010 study by Bawazeer et al. reported the outcome
of 21 eyes of 11 male patients with uveitis due to BD,
treated with adalimumab therapy [68]. Within four weeks
of commencing therapy 10 of the 11 patients exhibited
complete resolution of inflammation. Adalimumab was
well tolerated in this series, with no patients experiencing
any serious adalimumab-related side effects. This is most
likely due to adalimumab being a human-derived prepar-
ation. In addition, adalimumab enabled dosages of concur-
rent immunosuppressive agents and corticosteroids to be
reduced in many patients, and stopped completely in six
and three patients respectively. Despite these promising
results, it must be acknowledged that the study size was
small and larger randomised controlled trials should be
undertaken.
Etanercept
Etanercept (Enbrel; Immunex Corporation, Thousand
Oaks, CA, USA) is a fusion protein of two p75 TNF re-
ceptors and an Fc molecule that blocks the action of
TNF- α. Etanercept has primarily been investigated in
the management of mucocutaneous and articular mani-
festations in patients with BD [43]. A twice-weekly
20 mg subcutaneous injection has previously been
shown to be effective in the management of uveitis, as
well as for mucocutaneous and gastrointestinal disease
manifestations [44].
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A number of case studies using etanercept in BD-
associated uveitis have been reported [69–71]; the largest
of these reported outcomes for 10 patients with severe
uveitis in whom combination therapy with corticosteroid,
azathioprine and cyclosporine-A had been ineffective [70].
Adding etanercept to the treatment regimen led to a re-
duction in ocular inflammation, improving visual acuity
and allowing the corticosteroid dose to be reduced. How-
ever, after etanercept was stopped, uveitis returned in all
patients within 6 months. Patients also suffered similar
side effects to those experienced with other anti-TNF-α
agents, which are summarized in Table 1. Paradoxically,
etanercept-induced ocular inflammation has also been re-
ported in non-BD cohorts. The underlying mechanism for
this pro-inflammatory effect is not fully understood [72].
As a result of such observations, etanercept is not
routinely used as a first-line agent in the management
of BD-related uveitis: In a 2014 systematic review,
Levy-Clarke et al. made recommendations for the use
of anti-TNF biologic agents in patients with ocular
inflammatory conditions. Infliximab and adalimumab
were suggested as first line for patients with refractory
BD-associated uveitis, and etanercept as second line
owing to its lower success rates [73].
Golimumab
Golimumab (Simponi; Janssen Biotech, Inc.) is a mono-
clonal antibody to TNF-α that is administered subcuta-
neously once-monthly at a dose of 50 mg. Mesquida et
al. reported a single case of Behçet’s associated uveitis
successfully treated with golimumab injections [74]. In
this case uveitis was refractory to other TNF-α
inhibitors, but inflammation resolved after golimumab
injections were commenced. In addition, the dosage of
adjunctive cyclosporine-A was reduced to 150 mg/day,
and Prednisone to 5 mg/day. After six months treat-
ment the uveitis remained quiescent and the patient
remained asymptomatic with 6/6 visual acuity. The
side-effect profile of golimumab is similar to other anti-
TNF- α therapy (Table 2).
In a more recent study, Santos-Gómez et al. demon-
strated the efficacy of golimumab in four patients with
BD-associated uveitis. This study reported outcomes of
seven patients with refractory BD-associated uveitis in
whom adalimumab and/or infliximab had been ineffective
or poorly tolerated. Seven of 124 patients were treated
with alternative biologic agents, of which four received
golimumab, two received tocilizumab and one received ri-
tuximab. All seven cases achieved complete remission of
uveitis at one year of follow-up. Furthermore, mean best-
corrected visual acuity improved from 0.71 ± 0.24 Log-
MAR at baseline to 0.92 ± 0.13 LogMAR at three months
follow-up (p = 0.03). Therapy was well tolerated with no
serious side effects reported. The authors suggest that
golimumab may therefore be effective in managing BD-
associated uveitis that is refractory to standard therapies
and other biologic agents [75].
Specific receptor antagonists
Rituximab
Rituximab (Rituxan; Genentech, Inc., South San Francisco,
CA, USA) is a monoclonal antibody to CD20, which acts
through depletion of B-cells [76, 77]. There is limited pub-
lished evidence to support its use for uveitis in BD.
Sadreddini et al. reported outcomes in a single pa-
tient with loss of vision due to retinal vasculitis resist-
ant to prednisolone and azathioprine, who was treated
successfully with rituximab, achieving 24 months of
disease remission [78]. Davatchi et al. later performed a
randomized, single blind pilot study involving 20 pa-
tients with retinal vasculitis resistant to cytotoxic drugs
[79]. Patients were randomized to receive either two
courses of rituximab at a dose of 1000 mg at 15-day in-
tervals in combination with oral prednisolone (0.5 mg/
kg/day) and methotrexate (15 mg/week), or combin-
ation therapy comprising cyclophosphamide (1000 mg/
month), azathioprine (2-3 mg/kg/day) and prednisolone
(0.5 mg/kg/day). The primary outcome was measured
using the Total Adjusted Daily Activity Index (TADAI),
showing a statistically significant improvement in TADAI
score for patients receiving rituximab but not those on
traditional combination therapy. No statistically significant
difference was reported in improvement of retinal vascu-
litis between treatment groups, and both groups demon-
strated a similar statistically significant improvement in
macular oedema. Whilst this study suggests that rituximab
may be superior to combination therapy in controlling
overall disease activity, there is insufficient evidence to
suggest that it is superior to combination therapy for con-
trol of intra-ocular inflammation.
In this series, two patients experienced conjunctivitis
in the first week following rituximab infusion, one de-
veloped pneumonia and one developed herpes zoster,
both four months following treatment. Mild infusion-
related reactions were observed in two patients [79].
Tocilizumab
Evidence for the use of Tocilizumab (Actemr; Genentech,
Inc.), a monoclonal antibody against the IL-6 receptor, is
limited but encouraging [45–47, 80, 81]. In 2014 a study
reported 3 women with Behçet’s uveitis who were resistant
to immunosuppressive therapy and one anti-TNF bio-
logic. Following treatment with intravenous tocilzumab,
a reduction in ocular inflammation was observed in all
patients, being sustained for a mean period of 7.3 months
[45]. Other case reports also offer support for the use of
Tocilizumab for recurrent or resistant BD at a dose of
4-12 mg/kg every 2–4 weeks [40, 45, 46, 80]. Reported
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side effects are relatively minor and include infections
and hypersensitivity reactions.
Anakinra
Anakinra (Kineret; Swedish Orphan Biovitrum AB [publ],
Stockholm, Sweden) is an IL-1 receptor antagonist and its
use has only recently been reported in BD [82]. The drug
prevents IL-1-mediated activation of the immune re-
sponse. In a study by Cantarini et al. 9 patients with BD
refractory to TNF inhibitors were treated with a 1 mg/kg
daily subcutaneous injection of anakinra. Eight of nine
patients displayed resolution of disease activity within
4 weeks of injection, and no adverse events were reported
throughout the follow-up period. These results are espe-
cially promising since all 5 patients who began anakinra
therapy specifically for management of BD-related uveitis
demonstrated complete resolution of ocular inflammation.
Further studies are required in this area.
Daclizumab
Daclizumab (Zenapax; Hoffman-La Roche Ltd., Basel,
Switzerland) is a humanized monoclonal antibody to
the alpha subunit of the IL-2 receptor on the surface of
T-cells, administered intravenously, at a starting dose
of 1 mg/kg once every 2 weeks, with dose and fre-
quency titrated to response and side effects to a max-
imum of 200 mg [83]. It has been shown to be well
tolerated by patients in the management of uveitis, with
side effects including lymphadenopathy, psoriaform
rashes, mild peripheral oedema and infections [84]. The
data for efficacy of daclizumab in management of uveitis
due to BD has been equivocal [85–88]; Buggage et al.
completed a double-masked, randomized controlled trial,
concluding that daclizumab was less effective than placebo
in the management of ocular complications of BD [87].
Despite showing promise in the treatment of non-Behçet’s
uveitis, daclizumab was discontinued by the manufacturer
in 2009 due to decreasing market demand.
Cytokine inhibitors
Canakinumab
Canakinumab (Ilaris; Novartis International AG) is a hu-
man monoclonal antibody against IL-1β. Canakinumab
neutralizes IL-1β by competitively binding to the IL-1 re-
ceptor and consequently blocking the signaling by the
antigen:antibody complex [89]. In a recent case report
canakinumab was demonstrated to be effective in treating
BD-associated panuveitis [90]. The patient was a 16-year-
old female with severe bilateral panuveitis, with hypopyon
and retinal vasculitis. The patient had been treated with
other agents without success, including IFN-α, conven-
tional corticosteroid therapy combined with immunosup-
pressants, infliximab, adalimumab and anakinra. However,
a single subcutaneous injection of 150 mg canakinumab
resulted in complete resolution of inflammation lasting
8 weeks with an associated improvement in visual acuity.
A more recent study by Fabiani et al. (2017) investi-
gated the efficacy of both canakinumab and anakinra in
treating BD-related uveitis [91]. A total of 31 affected
eyes from 19 patients were treated with canakinumab,
anakinra or both. For seven patients, IL-1 inhibitor ther-
apy was their first exposure to biologic therapy. The
remaining 12 patients had previously received other bio-
logic agents. After 12 months of IL-1 inhibitor therapy
the number of ocular inflammatory flares had reduced
from 200 episodes/100 patients/year to 48.7 episodes/
100 patients/year (p < 0.0001). The authors concluded
that IL-1 inhibitor therapy is effective for managing re-
fractory BD-related uveitis, providing long-term control
of ocular inflammation.
Gevokizumab
Gevokizumab (XOMA 052; XOMA Corporation, Berkeley,
CA, USA) is a monoclonal antibody against IL-1β.
Gevokizumab reduces the binding affinity of IL-1β to
its receptor by occupying an allosteric site on the IL-1β
molecule, the resulting complex has reduced affinity for
the IL-1 receptor [89]. A 98-day pilot study followed 7
patients with Behçet’s uveitis resistant to cyclosporine-
A and azathioprine. A single 0.3 mg/kg infusion of
gevokizumab resulted in complete resolution of intra-
ocular inflammation within a median duration of
14 days (range 4–21 days), with a median duration of
response of 49 days, with one patient remaining disease
free for the full 97 days of follow-up [92].
In 2015 the results of a phase III, double-masked, pla-
cebo controlled trial studying the use of gevokizumab
in Behçet’s uveitis were reported online [93]. This
demonstrated a failure to achieve the primary outcome
of increasing time to first exacerbation of ocular in-
flammation. Whilst the authors described promising
secondary outcomes of an improvement in visual acuity
and reduction in the overall number of uveitis exacer-
bations, there is currently insufficient evidence to sup-
port widespread use of gevokizumab in uveitis due to
BD. To date, the results of this trial of not been pub-
lished in a peer-reviewed format.
Few adverse reactions have been reported for gevoki-
zumab, with infections and hypersensitivity reactions
being the most common [94].
Secukinumab
Secukinumab (AIN457; Novartis International AG) is a
human, monoclonal antibody against IL-17A [95, 96]. The
SHEILD study was a randomised, placebo-controlled,
multicentre phase III trial involving 118 patients with uve-
itis due to BD, in which secukinumab was administered
subcutaneously at a dose of 300 mg 2- or 4- weekly [97].
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The primary outcome was defined as reduction in uveitis
recurrence or vitreous haze score on concomitant with-
drawal of immunosuppressive therapy; unfortunately this
was not achieved and as a result, secukinumab is not cur-
rently employed in the management of uveitis in BD.
Interferons
Interferon-α
Evidence for the use of interferon (IFN) α-2a, a cytokine
modulating the immune response, is promising. A treat-
ment regimen of 6–9 MIU/day for 7 days, tapered down
to 3 MIU 3 times a week and then discontinued accord-
ing to treatment response has proven effective [48]. A
systematic review of 32 original-reports and 3 selected
abstracts between 1986 and 2002 has previously been
published [98]; in this review, 182 patients with Behçet’s
uveitis receiving IFN-α were identified, of whom 94%
exhibited partial or complete remission of their intra-
ocular inflammation. The review also demonstrated that
higher doses of IFN- α (30.3 ± 31.7 × 106 IU (median,
24 × 106; range 6–12 × 106 IU) per week)) were associ-
ated with long-term remission of up to 56 months once
treatment was discontinued, compared to lower doses
(16.2 ± 28.8 × 106 IU per week (median, 3 × 106; range,
2.8–64 × 106 IU)). Meta-analysis was limited due to vari-
ation in study design, however the authors concluded
that there was significant support for the use of IFN-α
treatment of uveitis associated with BD [99]. Other stud-
ies published since this review have also strongly sup-
ported the use of IFN- α in Behçet’s uveitis [48, 99–115].
Kotter et al. demonstrated the benefits of IFN-α in the
management of both ocular and extra-ocular manifesta-
tions of BD [99]; this study followed 50 patients who
were treated with IFN-α-2a. In affected eyes (n = 79) the
mean visual acuity rose significantly from 0.56 at week 0
to 84.0 at week 24 (P < 0.0001). Of these 79 eyes, 37
remained stable after 108 weeks. 46 of the participants
with ocular manifestations demonstrated a response to
treatment, demonstrating a 92% success rate. This study
also reported improvement in control of extra-ocular
disease manifestations with IFN-α-2a therapy, and en-
abled concurrent corticosteroid dose to be reduced.
Two studies conducted by Deuter et al. have demon-
strated an ability to achieve long-term remission of
Behçet’s uveitis with IFN- 2α therapy [106, 107]: In their
2010 study of 53 patients (96 eyes) with Behcet’s uveitis,
IFN-2α was initially administered at a dose of 6 million
IU per day, being tapered to a maintenance dose of 3
million IU twice per week, and then discontinued ac-
cording to treatment response. During a median follow
up period of 6.0 years (range 2.0 to 12.6 years) visual
acuity improved or remained stable in 91 of 96 eyes.
Complete remission of ocular inflammation was demon-
strated in 50% of patients 46 months after cessation of
the first IFN-2α course. It was concluded that IFN-2α ther-
apy is able to induce long-lasting remission of ocular-BD
while also significantly improving visual prognosis [107].
Further evidence of long-term efficacy was demonstrated
in a 2016 study by Kavandi et al. The authors reported on 8
patients whose visual acuity had improved or stabilised as a
result of IFN-α-2a therapy, demonstrating that disease
remained in remission with no adverse effects of therapy
2 years after IFN-α-2a discontinuation [114].
Interferon therapy has also been shown to enable reduc-
tion of concurrent corticosteroid dose. In a multicentre
study by Lightman et al. outcomes of 72 patients were
reported, demonstrating that the corticosteroid dose in
patients receiving interferon therapy could be reduced to
6.5 mg/day compared to 10 mg/day in those receiving
non-interferon therapy [115].
Support for the use of IFN-α to treat uveitis in BD is
therefore increasing; current data reveals response rates
of between 80% and 90% with a low relapse rate on ces-
sation of treatment. In addition, the use of IFN-α allows
oral steroid doses to be reduced, thus improving quality
of life for the patient. Furthermore, IFN-α has also been
shown to simultaneously improve other systemic mani-
festations of BD. However, potentially severe side effects
such as flu-like symptoms, bone marrow suppression
and injection-site reactions have been reported. Rarely,
severe depression and suicidal ideation have also been
reported [116]. Therefore, more clinical trials – ideally
randomised, placebo controlled trials – must be carried
out before an informed decision can be made about the
routine use of IFN-α in uveitis due to BD.
Effect of biologic therapies on quality of life in Behçet’s
uveitis
Uveitis affects between 50% and 90% of BD sufferers de-
pending on the geographic location of the population [41].
Up to 30% of patients with uveitis experience significant
visual impairment or legal blindness [115]. In addition to
a reduced visual acuity, patients may also suffer from
decreased contrast sensitivity, increased light sensitivity,
loss of depth and colour perception, floaters, glare and
loss of visual field. Uveitis therefore has a significant
impact on vision-related quality of life [36].
Biologic therapies have been shown to have a signifi-
cantly positive impact on quality of life in patients suf-
fering from uveitis due to BD. A study by Sakai et al.
reported a positive impact on health-related quality of
life (HR-QOF) and vision-related quality of life (VR-QOF)
in patients with Behçet’s uveitis treated with infliximab
[117]; twenty patients suffering from frequent uveitis at-
tacks due to BD were asked to complete the EuroQol-5D
questionnaire (EQ-5D) and the 25-item National Eye
Institute Visual Function Questionnaire (NEI VFQ-25),
before treatment and at 6 months and 12 months after
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treatment. The EQ-5D score improved from 0.66 ± 0.17
during the 6-month period prior to treatment to
0.97 ± 0.08 and 0.96 ± 0.07 at 6 and 12 months following
treatment demonstrating a significant improvement in
quality of life (P ≤ 0.0001). The authors also demonstrated
improvements in general and mental health.
Lightman et al. also demonstrated an improvement in
quality of life for patients on interferon therapy com-
pared to standard therapy after 36 months follow-up
[115]. The study found that interferon therapy allowed
the tapering down of corticosteroid and immunosup-
pressive doses without an increase in relapse rate and
alongside significant improvement in BD-related qual-
ity of life scores (p = 0.008).
Since there is no known cure for BD at present, the aim
of the treating clinician should be to maximise function
and maintain or improve quality of life for all patients.
There is a growing body of evidence to suggest that
biologic therapies may be an effective method of achieving
both aims.
Conclusion
The treatment of BD-associated uveitis, and the outlook
for patients, has markedly improved over recent decades.
With the advent of new technologies, biologic medications
offer an exciting and effective therapy. Until recently, bio-
logic therapies have been used mainly as an alternative
treatment after immunosuppressive and corticosteroid
therapies have failed, however accumulating evidence sup-
ports their use as first line agents. There are numerous
benefits to the use of biologics, particularly with regard to
quality of life and duration of treatment effect.
Whilst the benefits of biologic therapies compared to
conventional immunosuppressive treatment are evident
in terms of patient outcomes, their high cost may prove
to be a limiting factor in their widespread adoption,
with annual costs of biologic therapies often exceeding
£100,000 (Table 2). Clinicians are increasingly having to
make difficult decisions about whether to offer new and
expensive biologic therapies, or to continue with more
established agents that are cheaper due to the financial
restrictions enforced by healthcare authorities [118].
Undoubtedly, large multicentre and well-designed
studies are needed to develop further our understand-
ing of both Behçet’s uveitis and biologic therapies, re-
sponse rates and their long-term outcomes [1, 40]. It is
hoped that further research will develop a biologic
therapy that is universally effective, rapidly acting, has
few side effects and is affordable, ultimately improving
both clinical and quality of life outcomes for patients.
Abbreviations
BD: Behçet’s disease; IFN: Interferon; IL: Interleukin; QoL: Quality of life;




Robert Barry is supported by a NIHR Clinical Lectureship.
Availability of data and materials
Not applicable.
Authors’ contributions
TWM and RJB performed the literature search and were major contributors
in writing the manuscript. All authors contributed to the final manuscript.
All authors read and approved the final manuscript.





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1University of Birmingham Medical School, University of Birmingham,
Birmingham, UK. 2Behcet’s Centre of Excellence, City Hospital, Sandwell &
West Birmingham Hospitals NHS Trust, Birmingham, UK. 3Birmingham &
Midland Eye Centre, City Hospital, Sandwell & West Birmingham Hospitals
NHS Trust, Birmingham, UK. 4University of Birmingham Academic Unit of
Ophthalmology, Birmingham & Midland Eye Centre, City Hospital, Sandwell &
West Birmingham Hospitals NHS Trust, Birmingham, UK. 5Centre for
Translational Inflammation Research, School of Inflammation and Ageing,
College of Medical and Dental Sciences, University of Birmingham, Queen
Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust,
Birmingham, UK. 6Department of Ophthalmology, Queen Elizabeth Hospital,
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Received: 7 February 2017 Accepted: 7 July 2017
References
1. Barry RJ, Markandey B, Malhotra R, Knott H, Joji N, Mubin M, et al. Evidence-
based practice in Behçet’s disease: identifying areas of unmet need for 2014.
Orphanet J Rare Dis. 2014;9:16.
2. Krause I, Weinberger A. Behçet's disease. Curr Opin Rheumatol.
2008;20(1):82–7.
3. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. NEJM.
1999;341(17):1284–91.
4. Yurdakul S, Hamuryudan V, Yazici H. Behçet syndrome. Curr Opin
Rheumatol. 2004;16:38.
5. Feigenbaum A. Description of Behçet's syndrome in the Hippocratic third book
of endemic diseases. Br J Ophthalmol. 1956;40:355.
6. Wechsler B, Davatchi F, Mizushima Y, Hamza M, Dilsen N, Kansu E, et al.
Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.
7. Direskeneli H. Behçet's disease: infectious aetiology, new autoantigens,
and HLA-B51. Ann Rheum Dis. 2001;60:996.
8. Al-Araji A, Kidd DP. Neuro-Behçet's disease: epidemiology, clinical characteristics,
and management. Lancet Neurol. 2009;8(2):192–204.
9. Yazici Y, Yurdakul S, Yazici H. Behçet’s syndrome. Curr Rheumatol Rep.
2010;12(6):429–35.
10. Mok CC, Cheung TC, Ho CT, Lee KW, Lau CS, Wong RW. Behçet's disease in
southern Chinese patients. J Rheumatol. 2002;29:1689.
11. Salvarani C, Pipitone N, Catanoso MG, Cimino L, Tumiati B, Macchioni P, et al.
Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area
of northern Italy: a seventeen-year population-based study. Arthritis Rheum.
2007;57:171.
McNally et al. Orphanet Journal of Rare Diseases  (2017) 12:130 Page 9 of 12
12. Olivieri I, Leccese P, Padula A, Nigro A, Palazzi C, Gilio M, et al. High prevalence
of Behçet's disease in southern Italy. Clin Exp Rheumatol. 2013;31:28.
13. Savey L, Resche-Rigon M, Wechsler B, Comarmond C, Piette JC, Cacoub P, et
al. Ethnicity and association with disease manifestations and mortality in
Behçet's disease. Orphanet J Rare Dis. 2014;9:42.
14. Akpolat T, Koç Y, Yeniay I, Akpek G, GüllüI KE, et al. Familial Behçet's disease.
Eur J Med. 1992;1:391.
15. Koné-Paut I, Geisler I, Wechsler B, Ozen S, Ozdogan H, Rozenbaum M, et al.
Familial aggregation in Behçet's disease: high frequency in siblings and
parents of pediatric probands. J Pediatr. 1999;135:89.
16. Gülbay B, Acican T, Erçen Diken Ö, Pinar Önen Z. Familial Behçet's disease of
adult age: a report of 4 cases from a Behçet family. Intern Med. 2012;51:1609.
17. Gül A. Behçet's disease: an update on the pathogenesis. Clin Exp
Rheumatol. 2001;19(Suppl. 24):S6–S12.
18. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and
the risk of Behçet's disease: a systematic review and meta-analysis of case-
control genetic association studies. Arthritis Rheum. 2009;61:1287.
19. Evereklioglu C. Current concepts in the etiology and treatment of Behçet
disease. Surv Ophthalmol. 2005;50:297.
20. Suh CH, Park YB, Song J, Lee CH, Lee SK. Oligoclonal B lymphocyte
expansion in the synovium of a patient with Behçet's disease. Arthritis
Rheum. 2001;44:1707.
21. Ekşioglu-Demiralp E, Kibaroglu A, Direskeneli H, Yavuz S, Karsli F, Yurdakul S,
et al. Phenotypic characteristics of B cells in Behçet's disease: increased
activity in B cell subsets. J Rheumatol. 1999;26:826.
22. Direskeneli H, Hasan A, Shinnick T, Mizushima R, van der Zee R, Fortune F,
et al. Recognition of B-cell epitopes of the 65 kDa HSP in Behçet's disease.
Scand J Immunol. 1996;43:464.
23. Mumcu G, Inanc N, Aydin SZ, Ergun T, Direskeneli H. Association of salivary
S. Mutans colonisation and mannose-binding lectin deficiency with gender
in Behçet's disease. Clin Exp Rheumatol. 2009;27:S32.
24. Oflaz H, Mercanoglu F, Karaman O, Kamali S, Erer B, Genchellac H, et al.
Impaired endothelium-dependent flow-mediated dilation in Behçet's
disease: more prominent endothelial dysfunction in patients with vascular
involvement. Int J Clin Pract. 2005;59:777.
25. Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E.
Enhancement of endothelial cell E-selectin expression by sera from patients
with active Behçet's disease: moderate correlation with anti-endothelial cell
antibodies and serum myeloperoxidase levels. Clin Immunol. 1999;91:330.
26. Kansu E, Sahin G, Sahin F, Sivri B, Sayek I, Batman F. Impaired prostacyclin
synthesis by vessel walls in Behçet's disease. Lancet. 1986;2:1154.
27. Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, Biagi E, et
al. Behçet’s syndrome patients exhibit specific microbiome signature.
Autoimmun Rev. 2015 April;14(4):269–76.
28. Denniston AKO, Murray PI. Oxford Handbook of Ophthalmology. 3rd ed.
Oxford: Oxford University Press; 2009.
29. Nussenblatt RB. Uveitis in Behçet's disease. Int Rev Immunol. 1997;14:67.
30. Seyahi E, Melikoglu M, Yazici H. Clinical features and diagnosis of Behçet's
syndrome. Int J Adv Rheumatol. 2007;5:8.
31. Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. Behçet’s syndrome:
a critical digest of the 2014-2015 literature. Clin Exp Rheumatol. 2015;
33(Suppl. 94):S3–S14.
32. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and
frequency of blindness in patients with intraocular inflammatory disease. Br
J Opthalmol. 1996;80(4):332–6.
33. Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents
in the treatment of noninfectious uveitis. Biologics. 2014;8:67–81.
34. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu
M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol.
2004;138:373.
35. Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and
their management. Br J Ophthalmol. 1998;82(6):704–8.
36. Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I. Results of intravitreal
triamcinolone acetonide [IVTA] injection for the treatment of panuveitis attacks
in patients with Behçet disease. J Ocul Pharmacol Ther. 2007;23:395.
37. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA, et
al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;
149(3):423–32.
38. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN.
Effect of Infliximab on sight-threatening panuveitis in Behçet’s disease.
Lancet, 2001. 358(9278):295–6.
39. Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, et al.
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking
agents in the management of Behçet’s disease. Auto- immun Rev. 2015;14:1–9.
40. Barry RJ, Nguyen QD, Lee RW, Murray PI, Denniston AK. Pharmacotherapy
for uveitis: current management and emerging therapy. Clin Opth. 2014;8:
1891–911.
41. Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L, et al. Inhibition of
interleukin-1 by Canakinumab as a successful mono-drug strategy for the
treatment of refractory Behçet’s disease: a case series. Dermatology. 2014;
228:21–4.
42. Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon alpha in
Behçet disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):
320–35.
43. Sánchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Ríos-Fernández R,
Ortego-Centeno N. Off-label uses of anti-TNF therapy in three frequent
disorders: Behçet’s disease, Sarcoidosis, and noninfectious Uveitis. Mediat
Inflamm. 2013;2013:286857.
44. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-
term trial of Etanercept in Behçet's disease: a double blind, placebo
controlled study. J Rheumatol. 2005;32:98.
45. Calvo-Río V, de la Hera D, Beltrán-Catalán E, Blanco R, Hernandez M,
Martínez-Costa L, et al. Tocilizumab in uveitis refractory to other biologic
drugs: a study of 3 cases and a literature review. Clin Exp Rheum. 2014;32
Suppl 84:S54–7.
46. Addimanda O, Pipitone N, Pazzola G, Salvarani C. Tocilizumab for severe re-
fractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet. Semin
Arthritis Rheum. 2015;44:472–5.
47. Papo M, Bielefeld P, Vallet H, Seve P, Wechsler B, Cacoub P, et al.
Tocilizumab in severe and refractory non- infectious uveitis. Clin Exp
Rheumatol. 2014;32 Suppl 84:S75–9.
48. Park JY, Chung YR, Lee K, Song JH, Lee ES. Clinical experience of interferon
Alfa-2a treatment for refractory Uveitis in Behçet's disease. Yonsei Med J.
2015;56(4):1158–62.
49. Gul A. Behçet’s disease : an update on the pathogenesis. Clin Exp
Rheumatol. 2001;19(suppl 24):S6–12.
50. Yamashita N, Kaneoka H, Kaneko S, et al. Role of gammadelta T
lymphocytes in the development of Behçet’s disease. Clin Exp Immunol.
1997;107:241–7.
51. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte-
derive TNF-a, IL-6, IL-8 and increased neutrophil superoxide generation in
Behçet’s disease. A comparative study with familial Mediterranean fever and
healthy subjects. J Rheumatol. 1993;20:1544–9.
52. Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM. Systemic levels of the
T cell regulatory cytokines IL-10 and IL-12 in Behçet’s disease; soluble TNFR-75
as a biological marker of disease activity. J Rheumatol. 1997;24:128–32.
53. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-a, sIL-2R, OL-
6, and IL-8 are increased and associated with elevated lipid peroxidation in
patients with Behçet’s disease. Mediat Inflamm. 2002;11:87–93.
54. Chronopoulou H, Tzavara V, Oikonomopoulos N, et al. High levels of TNF-a
in the in the aqueous humor in patients suffering from Adamantiades-
Behçet’s disease: preliminary results. Invest Ophthalmol Vis Sci. 2001;
42(suppl 4)S708.
55. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous
humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic
Res. 2001;33:251–5.
56. Sukumaran S, Marzan K, Shaham B, Reiff A. High dose Infliximab in the
Treatment of Refractory Uveitis: Does Dose Matter? ISRN Rheumatol. 2012;
2012:765380.
57. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et
al. Efficacy, safety, and pharmacokinetics of multiple administration of
infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol.
2004;31(7):1362–8.
58. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A
prospective trial of Infliximab therapy for refractory uveitis: preliminary
safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903–12.
59. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG,
Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular
inflammation in Adamantiades-Behçet disease. Ann Intern Med.
2004;140(5):404–6.
60. Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis
PP. A single Infliximab infusion vs corticosteroids for acute panuveitis
McNally et al. Orphanet Journal of Rare Diseases  (2017) 12:130 Page 10 of 12
attacks in Behçet’s disease: a comparative 4-week study. Rheumatology
(Oxford). 2011;50(3):593–7.
61. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional
therapy in the management of retinal vasculitis in Behçet disease. Am J
Ophthalmol. 2008;146(6):845–50.
62. Hamza MM, Macky TA, Sidky MK, Ragab G, Soliman MM. Intravitreal
Infliximab in refractory Uveitis in Behçet’s disease: a safety and efficacy
clinical study. Retina. 2016;36(12):2399–408.
63. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman
MH, Kötter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR,
Stübiger N, Yurdakul S. Yazici H; EULAR expert committee. EULAR
recommendations for the management of Behçet disease. Ann Rheum
Dis. 2008;67(12):1656–62.
64. Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, et al.
Infliximab versus Adalimumab in the treatment of refractory inflammatory
Uveitis: a multicenter study from the French Uveitis network. Arthritis
Rheumatol. 2016;68(6):1522–30.
65. Rubbert-Roth A. Assessing the safety of biologic agents in patients with
rheumatoid arthritis. Rheumatology. 2012;51(Suppl 5):v38–47.
66. Olivieri I, Leccese P, D'Angelo S, Padula A, Nigro A, Palazzi C, et al. Efficacy
of Adalimumab in patients with Behçet's disease unsuccessfully treated with
Infliximab. Clin Exp Rheumatol. 2011;29:S54.
67. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-
threatening uveitis in Behçet’s disease. Eye [Lond]. 2007;21(6):824–5.
68. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with Adalimumab
in the treatment of ocular Behçet disease. Ocul Immunol Inflamm. 2010;
18(3):226–32.
69. Curigliano V, Giovinale M, Fonnesu C, Cerquaglia C, Verrecchia E, Turco S, et
al. Efficacy of Etanercept in the treatment of a patient with Behçet’s disease.
Clin Rheumatol. 2008;27:933–6.
70. Sfikakis P. Behçet’s disease: a new target for anti-tumour necrosis factor
treatment. Ann Rheum Dis. 2002;61 Suppl 2:ii51–3.
71. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al.
Tumour necrosis factor {alpha} inhibitors in the treatment of childhood
uveitis. Rheumatology (Oxford). 2006;45:982–9.
72. Gaujoux-Viala C, Giampetro C, Gaujoux T, Ea HK, Prati C, Orcel P, Wendling
D, Lioté F. Scleritis: a paradoxical effect of etanercept? Etanercept-associated
inflammatory eye disease. J Rheumatol. 2012;61 Suppl 2:ii51–3.
73. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN.
Expert panel recommendations for the use of anti-tumour necrosis factor
biologic agents in patients with ocular inflammatory disorders.
Ophthalmology. 2014;121(3):785–96.
74. Mesquida M, Victoria Hernández M, Llorenç V, Pelegrín L, Espinosa G, Dick
AD, et al. Behçet disease associated uveitis successfully treated with
Golimumab. Ocul Immunol Inflamm. 2013;21(2):160–2.
75. Santos-Gómez M, Calvo-Río V, Blanco R, Beltrán E, Mesquida M, Adán A.
The effect of biologic therapy different from infliximab or adalimumab
in patients with refractory uveitis due to Behcet’s disease: results of a
multicenter open label study. Clin Exp Rheumatol. 2016;34(6 Suppl 102):
S34–40.
76. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of
action and resistance. Oncogene. 2003;22(47):7359–68.
77. Kneitz C, Wilhelm M, Tony H. Effective B cell depletion with rituximab in
treatment of autoimmune diseases. J Immunobiol. 2002;206(5):519–27.
78. Sadreddini S, Noshad S, Molaeefard M, Noshad R. Treatment of retinal vasculitis
in Behcet’s disease with Rituximab. Mod Rheumatol. 2008;18(3):306–8.
79. Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F,
Nadji A, et al. Rituximab in intractable ocular lesions of Behçet’s
disease; randomized single-blind control study [pilot study]. Int J
Rheum Dis. 2010;13:246–52.
80. Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, et al. A case
of Behçet’s disease treated with a humanized anti- interleukin-6 receptor
antibody. Tocilizumab Mod Rheumatol. 2012;22:298–302.
81. Deroux A, Chiquet C, Bouillet L. Tocilizumab in severe and refractory
Behcet’s disease: four cases and literature review. Semin Arthritis Rheum.
2016;45(6):733–7.
82. Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al.
Anakinra treatment in drug-resistant Behçet’s disease: a case series. Clin
Rheum 2015;34:1293-1301.
83. Yang H, Wang J, Du J, et al. Structural basis of immunosuppression by the
therapeutic antibody daclizumab. Cell Res. 2010;20(12):1361–71.
84. Bhat P, Castañeda-Cervantes RA, Doctor PP, Foster CS. Intravenous
daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin
Exp Ophthalmol. 2009;247(5):687–92.
85. Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders
with daclizumab. Ophthalmology. 2003;110(4):786–9.
86. Sen HN, Levy-clarke G, Faia LJ, et al. High-dose Daclizumab for the
treatment of juvenile idiopathic arthritis–associated active anterior Uveitis.
Am J Ophthalmol. 2010;148(5):696–703.
87. Buggage RR, Levy-clarke G, Sen HN, et al. A double-masked, randomized study
to investigate the safety and efficacy of Daclizumab to treat the ocular
complications related to Behçet’s disease Ronald. Ocul Immunol Inflamm.
2007;15(2):63–70.
88. Wroblewski K, Sen HN, Yeh S, Faia L, Li Z, Sran P et al. Long-term
daclizumab therapy for the treatment of non-infectious ocular inflammatory
disease. Can J Opthalmol. 2011;46[4]:322–28.
89. Blech M, Peter D, Fischer P, Bauer MM, Hafner M, Zeeb M, et al. One target-
two different binding modes: structural insights into gevokizumab and
canakinumab interactions to interleukin-1β. J Mol Biol. 2013;425(1):94–111.
90. Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient
with juvenile Behçet’s syndrome with refractory eye disease. Ann Rheum
Dis. 2012;71(9):1589–91.
91. Fabiani C, Vitale A, Emmi G, Lopalco G, Vanozzi L, Guerriero S, et al.
Interleukin (IL)-1 inhibition with Anakinra and Canakinumab in Behçet’s
disease-related uveitis: a multicenter retrospective observational study. Clin
Rheumatol. 2017;36(1):191–7.
92. Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al.
Interleukin-1betaregulating antibody XOMA 052 [Gevokizumab] in the
treatment of acute exacerbations of resistant uveitis of Behçet’s disease: an
openlabel pilot study. Ann Rheum Dis. 2012;71(4):563–6.
93. XOMA. XOMA Announces Results From Phase 3 EYEGUARD™-B Study.
XOMA 2015. Available from url: http://investors.xoma.com/releasedetail.
cfm?ReleaseID=923200. Accessed 27 Feb 2016.
94. Zhou Z, Chen S, Shen N, Lu Y. Cytokines and Behçet’s disease. Autoimmun
Rev. 2012;11:699–704.
95. Kolls JK, Lindén A. Interleukin-17 family members and inflammation.
Immunity. 2004;21(4):467–76.
96. Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol
Immunol. 2010;7(3):164–74.
97. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of
noninfectious uveitis: results of three randomized, controlled clinical trials.
Ophthalmology. 2013;120(4):777–87.
98. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha
in Behçet disease: review of the literature. Semin Arthritis Rheum.
2004;33:320–35.
99. Kotter I, Vonthein R, Zierhut M, Eckstein A, Ness T, Gunaydin I, et al.
Differential efficacy of human recombinant interferon-alpha2a on ocular
and extraocular manifestations of Behçet disease: results of an open 4-
center trial. Semin Arthritis Rheum. 2004;33:311–9.
100. Kotter I, Zierhut M, Eckstein A, Vonthein R, Ness T, Gunaydin I, et al. Human
recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight
threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–31.
101. Onal S, Kazokogl H, Koc A, Akman M, Bavbek T. Direskeneli Hm et al. long-
term efficacy and safety of low-dose and dose-escalating interferon alfa-2a
therapy in refractory Behçet uveitis. Arch Ophthalmol. 2011;129:288–94.
102. Calguneri M, Ozturk M, Ertenli I, Kiraz S, Apras S, Ozbalkan Z. Effects of
interferon alpha treatment on the clinical course of refractory Behçet’s
disease: an open study. Ann Rheum Dis. 2003;62:492–3.
103. Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon
alfa combined with azathioprine for the uveitis of Behçet’s disease: an open
study. Isr Med Assoc J. 2003;4:928–30.
104. Wechsler B, Bodaghi B, Huong D, Fardeau C, Amoura Z, Cassoux N, et al.
Efficacy of interferon alfa-2a in severe and refractory uveitis associated with
Behçet’s disease. Ocul Immunol Inflamm. 2002;8:293–301.
105. Yalcindag F, Uzun A. Results of interferon alpha-2a therapy in patients with
Behçet’s disease. J Ocul Pharmacol Ther. 2012;28:439–43.
106. Deuter C, Kotter I, Gunaydin I, Zierhut M, Stubiger N. Ocular involvement in
Behçet’s disease: first 5-year-results for visual development after treatment
with interferon alfa-2a. Ophthalmologe. 2004;101:129–34.
107. Deuter C, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I. Long-term
remission after cessation of interferon-alpha treatment in patients with
severe uveitis due to Behçet’s disease. Arthritis Rheum. 2010;62:2796–805.
McNally et al. Orphanet Journal of Rare Diseases  (2017) 12:130 Page 11 of 12
108. Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Huong Du L.
Efficacy of interferon alpha in the treatment of refractory and sight
threatening uveitis: a retrospective monocentric study of 45 patients.
Br J Ophthalmol. 2007;91:335–9.
109. Krause L, Turnbull J, Torun N, Pleyer U, Zouboulis C, Foerster M. Interferon
alfa-2a in the treatment of ocular Adamantiades- Behçet’s disease. Adv Exp
Med Biol. 2003;528:511–9.
110. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa
therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol.
2006;244:1692–5.
111. Bielefeld P, Devilliers H, Deschasse C, Saadoun D, Sève P, Muselier A, et al.
Potential of Pegylated interferon alpha-2a in Behçet Uveitis: a report of five
cases. Ocul Immunol Inflamm. 2015Aug;24:1-4.
112. Aydinoglu-Candan Ö, Araz-Erşan B, Gul A, Badur S and Tugal-Tutkun I.
Anti-interferon alpha antibodies and autoantibodies in patients with
Behçet's disease uveitis treated with recombinant human interferon
alpha-2a. Graefes Arch Clin Exp Opthalmol. 2015Mar;253 [3]:457-65.
113. Hasanreisoglu M, Cubuk MO, Ozdek S, Guralik G, Aktas Z, Hasanreisoglu B.
Interferon alpha-2a therapy in patients with refractory Behçet Uveitis. Ocul
Immunol Inflamm. 2016;24:1–5.
114. Kavandi H, Khabbazi A, Kolahi S, Haiialilo M, Shavan FK, Oliaei M. Long-term
efficacy and safety of interferon α-2a therapy in severe refractory
ophthalmic Behçet’s disease. Clin Rheumatol. 2016;35(11):2765–9.
115. Lightman S, Taylor SR, Bunce C, Longhurst H, Lynn W, Stanford M, et al.
Pegylated interferon α-2b reduces corticosteroid requirement in patients
with Behcet’s disease with upregulation of circulating regulatory T cells and
reduction of Th17. Ann Rheum Dis. 2015;74(6):1138–44.
116. Keskin Y, Seyahi E, Poyraz C, Ugurlu S, Ozyazgan Y, Yazici H. Interferon alfa-
associated depression in patients with Behçet’s syndrome: a prospective
controlled study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S175.
117. Sakai T, Watanabe H, Kuroyanagi K, Akiyama G, Okano K, Kohno H, et al.
Health- and vision-related quality of life in patients receiving Infliximab
therapy for Behçet uveitis. Br J Ophthalmol. 2013;97(3):338–42.
118. Kelly CJ, Mr FA. Economics of biologic therapies. BMJ 2009;339:b3276.
Available from url: http://www.bmj.com/content/339/bmj.b3276. Accessed
13 Jan 2017.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
McNally et al. Orphanet Journal of Rare Diseases  (2017) 12:130 Page 12 of 12
